Felipe Vasudevan, MD
Accepting new patients

Felipe Vasudevan, MD

(he/him)
  • Internal Medicine
UCLA Health Westwood Internal Medicine |
200 Medical Plaza, Suite 420, Los Angeles, CA 90095
310-206-6232

About

Dr. Felipe Vasudevan completed an Internal Medicine & Addiction Medicine fellowship at NYU, and then ran an addiction consult service at Woodhull Hospital in Brooklyn, NY before directing the Addiction Consult Service & Bridge Clinic at UCLA Hospital. His interests include reducing barriers to pharmacotherapy and addressing stigma in the hospital setting for people who use drugs and improving access and visibility to methadone and contingency management programs.

Languages

English, Spanish

Education

Medical Board Certifications

Addiction Medicine, American Board of Preventive Medicine, 2022
Internal Medicine, American Board of Internal Medicine, 2019

Fellowship

Addiction Medicine, New York University School of Medicine, 2020

Residency

Internal Medicine, New York University School of Medicine, 2019

Degrees

MSc, NYU Langone Medical Center, 2022
MD, Boston University School of Medicine, 2016

Locations

UCLA Health Westwood Internal Medicine

310-206-6232
Fax:310-206-3551

Hospital Affiliations

Ronald Reagan UCLA Medical Center

Areas of Focus

Research

Publications

  1. Lee JD, Malone M, McDonald R, Cheng A, Vasudevan K, Tofighi B, Garment A, Porter B, Goldfeld KS, Matteo M, Mangat J, Katyal M, Giftos J, MacDonald R. Comparison of Treatment Retention of Adults With Opioid Addiction Managed With Extended-Release Buprenorphine vs Daily Sublingual Buprenorphine-Naloxone at Time of Release From Jail. JAMA Network Open. 2021 Sep 1;4(9): e2123032. doi: 10.1001/jamanetworkopen.2021.23032. PMID: 34495340; PMCID: PMC8427378.(Served as physician administering medication, interviewing patients and editor of final published work)
  2. Cheng A, Badolato R, Segoshi A, McDonald R, Malone M, Vasudevan K, Badiei B, Sugarman A, Macdonald R, Mangat J, Giftos J, Lee JD, Tofighi B. Perceptions and experiences toward extended-release buprenorphine among persons leaving jail with opioid use disorders before and during COVID-19: an in-depth qualitative study. Addict Sci Clin Pract. 2022 Jan 29;17(1):4. doi: 10.1186/s13722-022-00288-4. PMID: 35093164; PMCID: PMC8800291.(Helped in interviewing patients and editor of final published work)
  3. Avra, T., Torres, J., Vasudevan, K. F., & Samuels, E. A. (2024). “K Cramps,” Recurrent Abdominal Pain in a Patient with Chronic Ketamine Use: A Case Report. Clinical Practice and Cases in Emergency Medicine, 8(3), 277–281. https://doi.org/10.5811/cpcem.19431
  4. Avra, T., Vasudevan, F., Mukherjee, R., Morton, I., & Samuels, E. A. (2024). Off-Label Use of Lamotrigine and Naltrexone in the Treatment of Ketamine Use Disorder: A Case Report. Journal of Addiction Medicine. https://doi.org/10.1097/ADM.0000000000001359

Insurance

  • Aetna
  • Anthem Blue Cross
  • Blue Shield of California
  • Centivo
  • Cigna
  • First Health
  • Health Net of California
  • Interplan (part of HealthSmart)
  • L.A. Care
  • Medicare Advantage
  • MultiPlan
  • UFCM Health System
  • Prime Health Services
  • Private Healthcare Systems (PHCS)
  • TRICARE
  • UnitedHealthcare

The list of health care plans above may not be comprehensive and could change. 
Please contact your benefits coordinator or health insurance company directly to verify coverage.

Visit our health insurance information page for more details.